Sofinnova Partners Announces Third Investment From Its Italian Fund
04/20/20, 8:06 AM
Location
parisIndustry
medical device
medical
biotechnology
health care
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today an investment in Genespire, a Milan-based gene-therapy company developing best-in-class therapies for patients affected by genetic diseases. This is the third investment for the Sofinnova Telethon Fund, bringing the total financing of Italian startups by Sofinnova Partners to €25 million over the past six months. The Sofinnova Telethon Fund is the largest fund in Italy dedicated to biotechnologies, making early-stage investments in Italian companies targeting cures for rare and genetic diseases.
Company Info
Location
paris, ile de france, france
Additional Info
Julier is developing a next generation mechanical thrombectomy solution for the removal of thrombus and revascularization of patients experiencing Acute Ischemic Strokes. The core technology is derived from the work of two serial medtech entrepreneurs, Laurent Grandidier and Niall Behan.